BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dynavax Technologies Corporation (DVAX) Reports Second Quarter 2012 Financial Results


8/3/2012 9:43:35 AM

BERKELEY, CA--(Marketwire - August 01, 2012) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2012. The Company had $160.2 million in cash, cash equivalents and marketable securities as of June 30, 2012 as compared to $114.0 million at December 31, 2011. Total cash for the second quarter of 2012 included $69.6 million in net proceeds from the sale of 17,500,000 shares of common stock.

Total revenues were $2.7 million and $5.0 million for the three and six months ended June 30, 2012, respectively, compared to $7.3 million and $9.0 million, respectively, reported for the same periods of 2011. Revenues for the second quarter and first half of 2011 included a $6 million milestone earned under the Company's collaboration with GlaxoSmithKline.

Research and development expenses were $11.4 million and $23.8 million for the three and six months ended June 30, 2012, respectively. This compared to $13.3 million and $27.9 million, respectively, reported for the same periods of 2011. Research and development expenses decreased primarily due to the significant decline in clinical activities for HEPLISAV™.

General and administrative expenses were $6.0 million and $11.8 million for the second quarter and first half of 2012, respectively, compared to $4.1 million and $8.8 million, respectively, in the same periods of the prior year. General and administrative expenses increased primarily due to growth in commercial development expenses.

About HEPLISAV

HEPLISAV is an investigational adult hepatitis B vaccine for which a U.S. BLA has been accepted for review by the FDA and a Marketing Authorization Application (MAA) has been submitted. In Phase 3 trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known to enhance the immune response.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and earlier protection with fewer doses than currently licensed vaccines. For more information visit www.dynavax.com.

– tables to follow –

                                                                            
                                                                            
                      DYNAVAX TECHNOLOGIES CORPORATION                      
                   CONSOLIDATED STATEMENTS OF OPERATIONS                    
                  (In thousands, except per share amounts)                  
                                (Unaudited)                                 
                                                                            
                                  Three Months Ended     Six Months Ended   
                                       June 30,              June 30,       
                                 --------------------  -------------------- 
                                    2012       2011       2012       2011   
                                 ---------  ---------  ---------  --------- 
Revenues:                                                                   
  Collaboration revenue          $   1,623  $   6,363  $   2,552  $   6,729 
  Grant revenue                        882        890      1,969      1,779 
  Service and license revenue          179         16        513        505 
                                 ---------  ---------  ---------  --------- 
Total revenues                       2,684      7,269      5,034      9,013 
                                                                            
Operating expenses:                                                         
  Research and development          11,376     13,257     23,781     27,929 
  General and administrative         5,957      4,054     11,750      8,808 
  Amortization of intangible                                                
   assets                                -         54          -        299 
                                 ---------  ---------  ---------  --------- 
Total operating expenses            17,333     17,365     35,531     37,036 
                                 ---------  ---------  ---------  --------- 
                                                                            
Loss from operations               (14,649)   (10,096)   (30,497)   (28,023)
                                                                            
Interest income                         65         23        117         56 
Interest expense                      (589)      (487)    (1,176)      (977)
Other income (expense)                  63        (75)       (59)      (157)
                                 ---------  ---------  ---------  --------- 
                                                                            
Net loss                         $ (15,110) $ (10,635) $ (31,615) $ (29,101)
                                 =========  =========  =========  ========= 
                                                                            
Basic and diluted net loss per                                              
 share                           $   (0.09) $   (0.09) $   (0.20) $   (0.25)
                                 =========  =========  =========  ========= 
                                                                            
Shares used to compute basic and                                            
 diluted net loss per share        167,697    117,864    161,564    116,801 
                                 =========  =========  =========  ========= 
                                                                            
                                                                            
                                                                            
                                                                            
                      DYNAVAX TECHNOLOGIES CORPORATION                      
                         SELECTED BALANCE SHEET DATA                        
                               (In thousands)                               
                                 (Unaudited)                                
                                                                            
                                                    June 30,    December 31,
                                                      2012          2011    
                                                 ------------- -------------
Assets                                                                      
  Cash and cash equivalents and marketable                                  
   securities                                    $     160,199 $     113,961
  Property and equipment, net                            6,833         6,163
  Goodwill                                               2,356         2,312
  Other assets                                           6,507        11,666
                                                 ------------- -------------
Total assets                                     $     175,895 $     134,102
                                                 ============= =============
                                                                            
Liabilities and stockholders' equity                                        
  Accounts payable                               $       1,155 $       2,040
  Accrued liabilities                                    7,956         8,776
  Current portion of deferred revenue                    2,859         4,210
  Non-current portion of deferred revenue                5,312         6,386
  Short-term note payable to Holdings                   13,905        12,810
  Stockholders' equity                                 144,708        99,880
                                                 ------------- -------------
Total liabilities and stockholders' equity       $     175,895 $     134,102
                                                 ============= =============
                                                                            
                                                                            

Contacts:
Jennifer Lew
Vice President, Finance
510-665-7217
Email Contact

Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES